Merrimack Pharmaceuticals, Inc. MACK is scheduled to report second-quarter 2016 results on Aug 4. Last quarter, Merrimack delivered an earnings surprise of +15.38%. Let’s see how things are shaping up for the company this quarter.
Factors Influencing This Quarter
Merrimack’s only marketed product, Onivyde, gained approval in the U.S. in Oct 2015, in combination with fluorouracil (5-FU) and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas in patients who were previously treated with Eli Lilly and Company’s LLY Gemzar-based therapy.
The company’s efforts on commercializing Onivyde and driving awareness about the drug bode well. Merrimack has also been engaged in visiting key institutions, educating physicians, and providing active patient and oncology practice support services.
Sales of the drug are expected to increase in major academic centers. Inclusion of the drug in the National Comprehensive Cancer Network (NCCN) clinical practice guidelines in Oncology for pancreatic adenocarcinoma was a major boost to the company.
The guidelines recognized the product as category 1 second-line therapy for metastatic adenocarcinoma of the pancreas in patients who were previously treated with Gemzar-based therapy. This further validated the importance of the drug for patients suffering from metastatic pancreatic cancer. Consequently, the number...